Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating,
double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal
Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).
Phase:
Phase 2
Details
Lead Sponsor:
Christoph P Hornik, MD MPH
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) University of North Carolina, Chapel Hill